Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6

E Tsantikos, SA Oracki, C Quilici… - The journal of …, 2010 - journals.aai.org
The journal of immunology, 2010journals.aai.org
Lyn-deficient mice develop Ab-mediated autoimmune disease resembling systemic lupus
erythematosus where hyperactive B cells are major contributors to pathology. In this study,
we show that an inflammatory environment is established in Lyn−/− mice that perturbs
several immune cell compartments and drives autoimmune disease. Lyn−/− leukocytes,
notably B cells, are able to produce IL-6, which facilitates hyperactivation of B and T cells,
enhanced myelopoiesis, splenomegaly, and, ultimately, generation of pathogenic …
Abstract
Lyn-deficient mice develop Ab-mediated autoimmune disease resembling systemic lupus erythematosus where hyperactive B cells are major contributors to pathology. In this study, we show that an inflammatory environment is established in Lyn−/− mice that perturbs several immune cell compartments and drives autoimmune disease. Lyn−/− leukocytes, notably B cells, are able to produce IL-6, which facilitates hyperactivation of B and T cells, enhanced myelopoiesis, splenomegaly, and, ultimately, generation of pathogenic autoreactive Abs. Lyn−/− dendritic cells show increased maturation, but this phenotype is independent of autoimmunity as it is reiterated in B cell-deficient Lyn−/− mice. Genetic deletion of IL-6 on a Lyn-deficient background does not alter B cell development, plasma cell accumulation, or dendritic cell hypermaturation, suggesting that these characteristics are intrinsic to the loss of Lyn. However, hyperactivation of B and T cell compartments, extramedullary hematopoiesis, expansion of the myeloid lineage and autoimmune disease are all ameliorated in Lyn−/− IL-6−/− mice. Importantly, our studies show that although Lyn−/− B cells may be autoreactive, it is the IL-6–dependent inflammatory environment they engender that dictates their disease-causing potential. These findings improve our understanding of the mode of action of anti–IL-6 and B cell-directed therapies in autoimmune and inflammatory disease treatment.
journals.aai.org